INTRODUCTION AND OBJECTIVES: Prophylactic antibiotics are recommended in the American Urological Association (AUA) guidelines to reduce infectious complications following transrectal prostate biopsy (TRPB). Evidence for fluoroquinolone (FQ) prophylaxis is strong but high rates of FQ resistance worldwide have led to increased incidence of post-biopsy infections. Targeted antimicrobial prophylaxis based on rectal swab and culture can decrease rates of post-biopsy infections. To our knowledge, this will be the first study in North America to comprehensively analyze the cost utility of rectal swabs as a tool to reduce infectious complications after prostate biopsy.
INTRODUCTION AND OBJECTIVES: Fluoroquinolone (FQ)-resistant rectal vault flora has been associated with increased infectious complications in men undergoing transrectal ultrasound guided prostate needle biopsy (TRUS-PNB). We sought to determine the patient-related factors that predict FQ-resistant rectal swabs in men with an indication for TRUS-PNB.
METHODS: A retrospective review was performed on 5,271 consecutive patients who underwent rectal swabs before TRUS-PNB across 28 urology clinics around Chicago from January 2013 to December 2014. One microbiology lab processed all swabs, immersed them in a ciprofloxacin broth, and cultured them on MacConkey agar to isolate gram-negative rods. After incubation, FQ-resistant organisms were subcultured and underwent additional sensitivity testing. Characteristics of patients with and without FQ-resistant swabs were compared using the Kruskal Wallis and Chi-square tests. Multivariable logistic regression was performed to determine predictors of FQ resistance. Analyses were performed using R version 2.14.2 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS: Of the 5,271 rectal swabs analyzed, 4,164 (79%) were FQ sensitive, and 1,107 (21.0%) were resistant. On univariable analysis, increasing age, diabetes mellitus, antibiotic use within the past 6 months, and non-Caucasian race were predictors of FQ resistance (all p < 0.05). The number of prior biopsies, indwelling foley catheter, healthcare profession, and PSA were not predictors. FQ resistance was also associated with benign biopsy histology (p < 0.01 CONCLUSIONS: In this cohort increasing age, recent antibiotic-use, and Black and Hispanic races were independent predictors of FQ-resistance in the rectal vault. The higher likelihood of benign histology suggests that BPH or inflammation may be additional predictors and require further study.
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MP11-16 INDICATIONS, UTILIZATION, AND COMPLICATIONS FOLLOWING PROSTATE BIOPSY: A NEW YORK STATE ANALYSIS
INTRODUCTION AND OBJECTIVES: Uptake of active surveillance and changes in prostate cancer care may affect utilization of and complications following prostate needle biopsy (PNBx). We characterized recent trends and risk factors for PNBx complications using a statewide, all-payer cohort.
METHODS: We utilized the New York Statewide Planning and Research Cooperation System (SPARCS) to identify PNBx performed between 2011 and 2014 via transrectal (N¼9472) and transperineal (N¼421) approach. We characterized trends in utilization and complications using Poisson regression and Cochrane-Armitage tests. We used logistic regression to examine predictors of complications within 30 days of PNBx.
RESULTS: Ambulatory utilization of PNBx decreased over time (p<0.01). The most common indication for PNBx was elevated PSA (53.2%), followed by active surveillance for cancer (26.7%), abnormal DRE (2.6%) and atypia (1.6%). PNBx-associated infection rates increased from 2.6% to 3.5% during the study period (p¼0.02). Among repeat PNBx (n¼777), complication rates were comparable to initial PNBx. On multivariable analysis, patient race, procedure year, diabetes (OR 1.96, 95%CI 1.31-2.91, p<0.01), transrectal approach (OR 3.52, 95%CI 1.29-9.64, p¼0.01), and recent hospitalization (OR 2.03, 95%CI 1.43-2.89, p<0.01) were significantly associated with infections. Median total charge for infectious complications was $4,129 (interquartile range $711-$19,185).
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